Analysts Set Encompass Health Co. (NYSE:EHC) Price Target at $107.11

Shares of Encompass Health Co. (NYSE:EHC) have received an average recommendation of “Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $107.11.

Several equities research analysts recently commented on EHC shares. KeyCorp boosted their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Royal Bank of Canada increased their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. UBS Group upped their price target on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Barclays raised their price target on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th. Finally, Truist Financial reiterated a “buy” rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th.

Encompass Health Trading Down 0.5 %

NYSE:EHC opened at $91.85 on Tuesday. Encompass Health has a 12 month low of $66.36 and a 12 month high of $104.55. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm’s 50 day moving average is $99.00 and its 200 day moving average is $93.39. The stock has a market capitalization of $9.25 billion, a PE ratio of 22.19, a price-to-earnings-growth ratio of 1.30 and a beta of 0.86.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $0.94 by $0.09. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm earned $0.86 EPS. Sell-side analysts expect that Encompass Health will post 4.29 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be issued a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 0.74%. Encompass Health’s dividend payout ratio (DPR) is 16.43%.

Hedge Funds Weigh In On Encompass Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Panagora Asset Management Inc. bought a new stake in Encompass Health during the second quarter valued at $400,000. Commonwealth Equity Services LLC grew its position in Encompass Health by 1.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company’s stock worth $845,000 after purchasing an additional 123 shares during the last quarter. Drive Wealth Management LLC bought a new stake in Encompass Health during the 2nd quarter valued at $209,000. Natixis Advisors LLC grew its position in Encompass Health by 15.3% in the 2nd quarter. Natixis Advisors LLC now owns 94,002 shares of the company’s stock valued at $8,064,000 after buying an additional 12,495 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in Encompass Health by 14.4% in the second quarter. CIBC Asset Management Inc now owns 2,857 shares of the company’s stock worth $245,000 after purchasing an additional 360 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.